Therapeutic Potential of Tumor Suppressors in Treating Breast Cancer

Kunnath Ap

doi:10.19070/2167-9118-1800026

Abstract

Therapeutic Potential of Tumor Suppressors in Treating Breast Cancer

Highlights

Despite significant advances in early detection and treatment, breast cancer remains a major cause of morbidity and mortality in women
Mutations in tumor suppressor genes are one of the drivers of breast carcinogenesis and inherited mutations in p53, BRCA1 and BRCA2 significantly contribute to breast cancer risk [3, 4]
This review summarizes the major tumor suppressor genes associated with breast cancer and the therapeutic potential of these genes in breast cancer

Summary

Introduction

Despite significant advances in early detection and treatment, breast cancer remains a major cause of morbidity and mortality in women. Some oncoproteins and tumor suppressors directly regulate cell proliferation (either promoting or inhibiting), programmed cell death or apoptosis, and DNA repair [6] Increasing knowledge of these genes and their involvement with the neoplastic pathways has provided greater opportunities to develop targeted therapeutics, which offer higher specificity,. Since the BRCA1 and BRCA2 proteins share functional similarities, mutations in the encoding genes result in similar and specific hereditary predisposition to breast https://scidoc.org/IJCR.php and ovarian cancer. More than 1800 mutations have been identified in BRCA2, including frameshift deletions, insertions, or nonsense mutations that lead to premature truncation of proteins These events are consistent with the loss of function that is expected in mutations of tumor suppressor genes. Carriers of BRCA2 mutations have a higher risk of gallbladder, bile duct and stomach cancer, and melanoma [40]

Gene Therapy

Targeting the Downstream Sequences

Findings

Conclusion